New Jersey Court Advances Antitrust Case Against Celgene and Partners Over Revlimid Pricing Practices
In a notable development within the pharmaceutical industry, a New Jersey federal judge has denied motions to dismiss a complex antitrust multidistrict litigation (MDL) involving Celgene Corp.’s cancer medication Revlimid. The litigation accuses Bristol-Myers Squibb, Natco Pharma, AbbVie, and other pharmaceutical companies of engaging in “pay-for-delay” agreements, which allegedly delayed the entry of generic competitors…